GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Chromocell Therapeutics
Shares of Chromocell, a biotech company focused on pain treatment, are a highly speculative bet. Their price is driven not by financial performance, but by news from clinical trials of its non-opioid analgesics.
Share prices of companies in the market segment - Neuro
Chromocell Therapeutics is a biopharmaceutical company developing non-opioid drugs for the treatment of chronic pain. We've classified it in the "Neurology" category. The chart below shows how the market values companies seeking alternatives to traditional painkillers.
Broad Market Index - GURU.Markets
Chromocell Therapeutics is a biopharmaceutical company developing non-opioid drugs for the treatment of chronic pain. Its focus on this important issue makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Chromocell compares to it.
Change in the price of a company, segment, and market as a whole per day
CHRO - Daily change in the company's share price Chromocell Therapeutics
For Chromocell Therapeutics, a neuroscience company, daily price change is a measure of its enormous volatility. This metric reflects its extreme sensitivity to clinical trial data on its pain medications, and is key to assessing risk.
Daily change in the price of a set of shares in a market segment - Neuro
Chromocell Therapeutics is a biopharmaceutical company developing non-opioid analgesics. The pharmaceutical sector working on opioid alternatives is volatile. The chart below reflects the average fluctuations in this niche, helping to assess the risks and potential of CHROs.
Daily change in the price of a broad market stock, index - GURU.Markets
Chromocell is a biotech company working on treating neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Chromocell Therapeutics
For Chromocell Therapeutics, year-over-year performance is a reflection of its unique drug discovery platform. Its market cap change over the past 12 months depends on progress in its programs, particularly in pain management. Its valuation reflects its belief that its technology will lead to the discovery of new, non-opioid analgesics.
Annual dynamics of market capitalization of the market segment - Neuro
Chromocell, as a private biotech company, likely specializes in treating neurological diseases. Its growth depends on successful clinical trials. Its valuation dynamics will reflect investors' faith in its science, potentially outperforming the sector if successful, but with inherent biotech risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Chromocell Therapeutics is a biotech company whose value is based on the hope of developing a new pain treatment. Its year-over-year performance relative to the market isn't a reflection of business processes, but a speculative bet on clinical trial success. The chart is a series of sharp movements driven by news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Chromocell Therapeutics
Chromocell is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News of trial results for its drugs for neurological diseases are the main drivers.
Monthly dynamics of market capitalization of the market segment - Neuro
Chromocell Therapeutics is developing non-opioid analgesics. Finding effective and safe painkillers is one of the most important goals in the pharmaceutical industry. The chart below shows how investors assessed the prospects of companies trying to address the opioid crisis and the risks associated with developing pain medications.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Chromocell Therapeutics is a biotech company focused on neuroscience. Like other companies in this sector, its stock price will be driven not by market cycles, but by clinical trial milestones and investor confidence in the company's scientific platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Chromocell Therapeutics
Chromocell Therapeutics is a clinical-stage biotech company focused on treating pain and other neurological disorders. Its weekly stock price is highly volatile and depends entirely on clinical trial progress.
Weekly dynamics of market capitalization of the market segment - Neuro
Chromocell Therapeutics develops drugs for the treatment of pain and neurological disorders. Success in this area depends on passing complex clinical trials. The chart below shows whether Chromocell's share price movements are a reaction to news about its research or reflect general investor sentiment in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Chromocell is an early-stage biotech company. Its shares are buoyed by anticipation of research results. The chart clearly demonstrates how its performance is driven by scientific news rather than general market trends, creating its own unique path.
Market capitalization of the company, segment and market as a whole
CHRO - Market capitalization of the company Chromocell Therapeutics
Chromocell Therapeutics' market capitalization reflects its unique drug discovery platform, primarily in the field of pain management. As an early-stage company, its valuation is speculative and driven by news about its research progress. This is a bet that its technology will lead to the discovery of new, non-opioid analgesics.
CHRO - Share of the company's market capitalization Chromocell Therapeutics within the market segment - Neuro
Chromocell Therapeutics is an early-stage biotech company working in neuroscience. Its market capitalization is extremely small, which is typical for companies whose drugs have not yet reached the market. The chart reflects investor expectations and changes in their assessment of its scientific potential as research progresses.
Market capitalization of the market segment - Neuro
The graph below shows the market capitalization of the neurological pharmaceutical sector. Chromocell Therapeutics is a company developing new approaches to pain treatment. The dynamics of this market reflect the enormous need for effective, non-opioid analgesics. Chromocell is striving to fill its niche by offering innovative solutions to this complex medical problem.
Market capitalization of all companies included in a broad market index - GURU.Markets
Chromocell is a biopharmaceutical company developing drugs to treat neurological diseases. Its market capitalization reflects the potential of its research in this complex field. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
CHRO - Book value capitalization of the company Chromocell Therapeutics
Chromocell Therapeutics' foundation is its Chromovert® scientific platform and intellectual property for drugs for the treatment of rare neurological diseases. The book value represents the capital used to conduct clinical trials. The chart tells the story of a biotech company investing in the development of drugs for difficult-to-treat diseases.
CHRO - Share of the company's book capitalization Chromocell Therapeutics within the market segment - Neuro
Chromocell Therapeutics develops new analgesics. The chart shows its share of actual R&D assets. These are its laboratories, where the unique Chromovert platform is used to discover drugs for pain treatment, and these constitute its scientific base.
Market segment balance sheet capitalization - Neuro
Chromocell Therapeutics is a biotech company focused on treating neurological diseases. Their value lies in their research, not their manufacturing plants. A book value chart will show their R&D base, but it won't capture the potential value of their intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Chromocell Therapeutics' balance sheet includes laboratories and R&D centers for developing non-opioid analgesics. The chart shows how the company is building its scientific and material foundation to address chronic pain.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Chromocell Therapeutics
For Chromocell Therapeutics, a pain medication developer, assets are intellectual property. The chart below is a visualization of hope. The company's market valuation exists virtually independently of its modest book value, based entirely on expectations of breakthrough research and potential partnerships with pharmaceutical giants.
Market to book capitalization ratio in a market segment - Neuro
Chromocell Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of treatments for pain and other neurological diseases. Its valuation is based entirely on the potential of its scientific developments. The chart reflects the high risk and potential reward that investors are pricing in, ignoring the current holdings.
Market to book capitalization ratio for the market as a whole
Chromocell Therapeutics is an early-stage biotech company focused on neuroscience. Its value is derived almost entirely from its intellectual property and the potential for future drugs. This chart shows that its market valuation is not tied to current tangible assets but rather reflects investors' hopes for a scientific breakthrough.
Debts of the company, segment and market as a whole
CHRO - Company debts Chromocell Therapeutics
Chromocell Therapeutics is an early-stage biotech company leveraging its platform for drug discovery, particularly in pain treatment. This chart depicts its financial model. The company relies entirely on venture capital and equity to fund its preclinical research in hopes of achieving a scientific breakthrough.
Market segment debts - Neuro
Chromocell Therapeutics is a biotechnology company developing new analgesics. Finding effective and safe painkillers is one of the most challenging tasks in pharmacology, requiring significant R&D investment. This chart reflects the company's financial strategy for achieving a potential breakthrough in pain treatment.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Chromocell Therapeutics
Chromocell Therapeutics is a clinical-stage biopharmaceutical company working in neuroscience. This chart shows its financial structure. As with most biotechs without stable revenue, debt is a huge risk. All resources should be focused on research, not interest payments.
Market segment debt to market segment book capitalization - Neuro
Chromocell Therapeutics is a biopharmaceutical company developing drugs to treat neurological diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its expensive clinical research and development in this complex area of medicine.
Debt to book value of all companies in the market
Chromocell Therapeutics develops drugs for the treatment of neurological and pain disorders. Being in the early stages of research, the company is entirely dependent on external funding. This chart of total market debt demonstrates how favorable the investment climate is for raising capital for long-term, high-risk biotech projects.
P/E of the company, segment and market as a whole
P/E - Chromocell Therapeutics
Chromocell Therapeutics is a biotech company developing non-opioid analgesics for the treatment of chronic pain and cough. This chart reflects investor confidence in the development of effective and safe alternatives to opioids. Its performance is entirely dependent on the results of clinical trials of its experimental drugs.
P/E of the market segment - Neuro
Chromocell Therapeutics is a clinical-stage biotech company using its advanced platform to discover and develop non-opioid pain medications. Its goal is to create an effective alternative to opioids. This chart shows the average valuation for the neuroscience sector, reflecting how investors value efforts to address the pressing opioid crisis.
P/E of the market as a whole
Chromocell Therapeutics is a biopharmaceutical company developing drugs for the treatment of pain syndromes. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant. Chromocell's fate is decided in the lab.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Chromocell Therapeutics
Chromocell Therapeutics is a biotech company developing non-narcotic analgesics for the treatment of chronic pain. This chart reflects market expectations for the success of its clinical programs. Future profits depend on a breakthrough in creating an effective, safe, and non-addictive pain reliever.
%20P%2FE%20Chromocell%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Chromocell-Therapeutics&v=1772628032902 "Chart of the company's future (projected) P/E Chromocell Therapeutics")
Future (projected) P/E of the market segment - Neuro
Chromocell Therapeutics is a biopharmaceutical company developing non-opioid analgesics for the treatment of chronic pain. The chart reflects average profitability expectations for the biotech sector. Chromocell's position relative to this benchmark reflects the market's assessment of their chances of developing an effective and safe pain reliever that will serve as an alternative to existing medications.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772628033001 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
ChromoCell Therapeutics is a preclinical biotech company developing new treatments for rare neurological diseases using its unique drug screening platform. This chart of overall market expectations shows how willing investors are to invest in early-stage research projects, where the risks are highest.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772628033122 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Chromocell Therapeutics
Chromocell Therapeutics is a clinical-stage biopharmaceutical company developing non-narcotic analgesics for the treatment of chronic pain. Its current financial schedule consists of research and development expenses. Potential profitability is entirely dependent on the success of developing an effective and safe pain reliever.
Profit of companies in the market segment - Neuro
Chromocell Therapeutics is a clinical-stage biopharmaceutical company developing non-opioid analgesics for the treatment of chronic pain. This is a highly sought-after but complex area. This chart shows the total revenue in its sector, illustrating the level of investor confidence in the commercial potential of opioid-free treatments for complex neurological conditions.
Overall market profit
Chromocell Therapeutics is a biotech company developing drugs to treat rare neurological diseases. Its value and prospects depend on the success of clinical trials, not on current economic cycles. However, the positive backdrop created by the growth in overall profitability on this chart facilitates raising capital to fund expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Chromocell Therapeutics
Chromocell Therapeutics is a clinical-stage biotech company developing non-opioid analgesics for pain treatment. Future profits are entirely dependent on the success of its developments. This chart reflects analysts' speculative expectations regarding the potential of its drugs as an alternative to opioids.
%20profit%20of%20the%20company%20Chromocell%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Chromocell-Therapeutics&v=1772628033350 "Graph of future (projected) profit of the company Chromocell Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Chromocell Therapeutics is a biotech company developing non-opioid analgesics for the treatment of chronic pain. Its success depends on the results of clinical trials and the need for alternatives to opioids. This chart reflects forecasts for the entire pharmaceutical sector, providing context for assessing Chromocell's potential to address this pressing medical need.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772628033390 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
ChromoCell Therapeutics develops drugs for the treatment of rare neurological diseases. The company's prospects at this stage depend entirely on the success of its scientific research and clinical trials. The macroeconomic indicators shown in this chart are not relevant for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772628033480 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Chromocell Therapeutics
Chromocell Therapeutics is an early-stage biotech company focused on neuroscience. With minimal revenue, its valuation, as shown in this chart, reflects pure hope. Investors are betting on the success of its scientific platform and the potential to create a breakthrough drug for the treatment of difficult-to-treat diseases.
P/S market segment - Neuro
Chromocell Therapeutics is a biopharmaceutical company developing non-narcotic analgesics for the treatment of pain. Future revenue depends on the success of its clinical programs. This chart for the neuroscience sector compares investor expectations for Chromocell's innovative approach with those of other companies working in this complex field.
P/S of the market as a whole
ChromoCell Therapeutics is a biopharmaceutical company developing novel non-narcotic analgesics for the treatment of chronic pain. Its approach is based on ion channel modulation. This market revenue valuation chart helps us understand how investors value the company's potential to create the effective and safe pain relief that medicine so desperately needs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Chromocell Therapeutics
ChromoCell Therapeutics is a biopharmaceutical company that uses its unique platform to discover and develop new drugs for the treatment of rare neurological diseases and pain syndromes. This chart shows how the market assesses the future commercial potential of its developments, relying on the success of clinical trials.
%20P%2FS%20Chromocell%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Chromocell-Therapeutics&v=1772628033785 "The graph of the company's future (projected) P/S Chromocell Therapeutics")
Future (projected) P/S of the market segment - Neuro
Chromocell Therapeutics is a clinical-stage biopharmaceutical company developing non-opioid analgesics for the treatment of chronic pain. The company's valuation is based on investors' belief in the potential of its lead candidate to address the significant unmet need for effective and safe pain relief, which carries high clinical risks.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772628033914 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Chromocell Therapeutics is a clinical-stage biotech company focused on pain management. Its value reflects expectations of future scientific breakthroughs. This chart reflects revenue forecasts for existing businesses, while Chromocell's value reflects the potential to create new medical markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772628033972 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Chromocell Therapeutics
Chromocell Therapeutics is a clinical-stage biotechnology company focused on developing non-opioid analgesics. The company currently has no commercial products and, therefore, no sales revenue. Any revenue shown in the chart may be due to funding from partners.
Sales of companies in the market segment - Neuro
Chromocell Therapeutics (CHRO) develops non-opioid analgesics for the treatment of chronic pain, targeting new biological targets. The company strives to create effective and safe painkillers. This chart shows revenue in the neuroscience pharmaceutical segment. Success at Chromocell could offer an alternative to opioids and capture a significant share of this vast market.
Overall market sales
Chromocell Therapeutics is a biotech company developing non-opioid analgesics. Its success depends on the results of clinical trials. However, the overall economic backdrop, reflected in this chart, influences the investment climate. During growth periods, investors are more inclined to fund the development of innovative drugs targeting large markets, such as pain management.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Chromocell Therapeutics
Chromocell Therapeutics is a clinical-stage biotechnology company developing non-narcotic analgesics for the treatment of chronic pain. Its future revenue is entirely dependent on the success of clinical trials and the commercialization of its drugs. This chart reflects analyst expectations, which are an assessment of the scientific potential and commercial prospects of its developments.
%20sales%20of%20the%20company%20Chromocell%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Chromocell-Therapeutics&v=1772628034236 "Schedule of future (projected) sales of the company Chromocell Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Chromocell Therapeutics is a clinical-stage biopharmaceutical company focused on pain management. This graph shows the potential future revenue from their pipeline. This is an analyst's view of the commercial prospects for their non-opioid analgesics.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772628034538 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
ChromoCell Therapeutics develops drugs for the treatment of neuropathic pain using its unique technology platform. The company is targeting a huge market with an unmet need. This chart illustrates the overall investment climate, but for ChromoCell, the key factor is scientific evidence of the efficacy and safety of its pain treatment approaches.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772628034588 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Chromocell Therapeutics
Chromocell Therapeutics is a biotech company developing non-opioid analgesics for the treatment of chronic pain. While in clinical trials, it incurs significant R&D expenses. The chart shows its current profitability, which represents an investment in the development of safe and effective pain medications of the future.
Market segment marginality - Neuro
Chromocell Therapeutics is a clinical-stage biotech focused on developing non-opioid analgesics. This chart reflects its operating expenses. As with other biotechs without revenue, the dynamics of this metric are important for assessing the effectiveness of capital management during drug development.
Market marginality as a whole
Chromocell Therapeutics is a biotech company developing non-narcotic analgesics. It is in the early stages and relies on research funding. This total return chart reflects investors' risk appetite. During periods of economic growth and high margins, capital is more likely to flow into innovative, but long-term and risky projects.
Employees in the company, segment and market as a whole
Number of employees in the company Chromocell Therapeutics
Chromocell Therapeutics is a biotechnology company developing novel non-narcotic analgesics. Its key assets are its scientific platform and team. This chart shows the size of the research team working to advance its innovative drug candidates through the preclinical and early clinical stages.
Share of the company's employees Chromocell Therapeutics within the market segment - Neuro
Chromocell Therapeutics is a biotechnology company developing drugs for neurological diseases. Its main asset during the research and development phase is its scientific team. This chart shows the amount of intellectual capital the company invests in its R&D programs, a key indicator of its scientific potential and stage of development.
Number of employees in the market segment - Neuro
Chromocell Therapeutics is developing non-opioid analgesics for pain treatment. This chart, reflecting activity in the neuroscience sector, demonstrates the intensity of the search for new pain relief methods. For Chromocell, the growing number of scientists in this field highlights the enormous need for effective and safe drugs that could serve as alternatives to opioids.
Number of employees in the market as a whole
Chromocell Therapeutics is developing new non-narcotic analgesics for pain treatment. The need for such drugs is enormous, but bringing them to market requires significant investment. A strong economy, reflected by the growth in overall employment in this chart, is fueling capital flows into the biotech sector, allowing companies like Chromocell to fund expensive clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Chromocell Therapeutics (CHRO)
Chromocell Therapeutics (CHRO) is another biotech company focused on neuroscience and rare diseases. Like its peers in the sector, this metric reflects the core of their business: intellectual property (IP) and R&D pipeline potential. The market doesn't value headcount, but rather the likelihood of creating a blockbuster, so high market cap per employee is the norm here.
%20of%20the%20company%20Chromocell%20Therapeutics%20(CHRO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Chromocell-Therapeutics-CHRO&v=1772628034864 "Chart of market capitalization per employee (in thousands of dollars) of the company Chromocell Therapeutics (CHRO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Chromocell Therapeutics develops drugs to treat neurological pain. In early-stage biotech, capitalization is a bet on a scientific breakthrough. This chart shows the enormous potential value investors place on the research of each company scientist working on an innovative drug.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772628034906 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
ChromoCell Therapeutics is a biotech company developing drugs to treat rare neurological diseases. Its market capitalization reflects investors' bet on its scientific platform. This chart for ChromoCell illustrates a biotech phenomenon: enormous market value is created by a small team of scientists who own valuable intellectual property.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772628034934 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Chromocell Therapeutics (CHRO)
Chromocell Therapeutics is an early-stage biotech company focused on pain treatment. Like most R&D companies, it is unprofitable. This graph will show a negative value—the loss per scientist. This is not an indicator of inefficiency, but rather an indication of the intensity of investment in research.
%20Chart%20Chromocell%20Therapeutics%20(CHRO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Chromocell-Therapeutics-CHRO&v=1772628035026 "Company Profit Per Employee (in thousands of dollars) Chart Chromocell Therapeutics (CHRO)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Chromocell Therapeutics develops new drugs for the treatment of neurological and pain disorders. In biotech, where research requires significant investment, the productivity of the research team is critical. This graph shows the financial return per employee, allowing one to assess the effectiveness of the company's research and development activities.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772628035112 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Chromocell Therapeutics is a biotech company developing drugs to treat rare neurological diseases and pain. Their value lies in their R&D platform. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772628035176 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Chromocell Therapeutics (CHRO)
Chromocell Therapeutics is a clinical-stage biopharmaceutical company developing non-opioid analgesics. Because it has no commercial products yet, revenue per employee is minimal or nonexistent. This chart clearly illustrates the R&D phase, where all value is generated through research and development in pain treatment.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Chromocell-Therapeutics-CHRO&v=1772628035380 "Sales chart per company employee Chromocell Therapeutics (CHRO)")
Sales per employee in the market segment - Neuro
Chromocell Therapeutics (CHRO) is a clinical-stage biotech company specializing in the development of non-opioid analgesics for the treatment of chronic pain. This chart shows the average revenue per employee in the sector. It is important for assessing the efficiency of capital utilization and personnel structure compared to other biotech companies working on pain relief.
Sales per employee for the market as a whole
Chromocell Therapeutics (CHRO) is a clinical-stage biotechnology company focused on developing non-opioid analgesics (painkillers) for the treatment of chronic pain. The company has no commercial revenue. This near-zero figure reflects ongoing investment in its team of scientists conducting R&D to create a new class of safe painkillers.
Short shares by company, segment and market as a whole
Shares shorted by company Chromocell Therapeutics (CHRO)
Chromocell Therapeutics (CHRO) is a clinical-stage biopharmaceutical company specializing in the development of non-opioid analgesics. Pain treatment is one of the most complex areas in R&D. This chart shows short interest. High values reflect enormous risks: investors are betting that the company's drugs will fail clinical trials, like many others before them. (349)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Chromocell-Therapeutics-CHRO&v=1772628035642 "Short Shares Chart for the Company Chromocell Therapeutics (CHRO)")
Shares shorted by market segment - Neuro
Chromocell Therapeutics (CHRO) is a biopharmaceutical company using its platforms to develop drugs for rare neurological diseases and pain. The chart below shows the overall short position across the biotech sector. It's a barometer of investor confidence in the success of risky clinical trials.
Shares shorted by the overall market
Chromocell is a biotech company searching for new (non-opioid) pain medications. It's a complex R&D operation. This chart reflects the overall market pessimism. When investors are fearful, they're unwilling to fund "long-term science." They see a "cash burn" and fear that funding for trials will run out before results are achieved.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Chromocell Therapeutics (CHRO)
Chromocell Therapeutics (CHRO) is a biotech company using its platform to discover new drugs, primarily for the treatment of pain and neurological disorders. This oscillator measures price momentum. It helps identify when enthusiasm (above 70) about trial data or disappointment (below 30) reaches extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Chromocell-Therapeutics-CHRO&v=1772628035758 "RSI 14 indicator chart for the company's stock Chromocell Therapeutics (CHRO)")
RSI 14 Market Segment - Neuro
Chromocell Therapeutics is a biotech company developing drugs to treat rare neurological diseases and pain. This chart measures the collective excitement in the neuroscience biotech sector. It helps determine whether the entire speculative segment is overheated by expectations of clinical success.
RSI 14 for the overall market
For Chromocell Therapeutics, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CHRO (Chromocell Therapeutics)
Chromocell Therapeutics is a biotech company developing non-narcotic painkillers. This chart shows the average 12-month forecast of analysts. It represents their collective speculative bet that their R&D platform will be able to create an effective alternative to opioids.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CHRO-Chromocell-Therapeutics&v=1772628035867 "A chart showing analyst consensus forecasts for the expected stock price. CHRO (Chromocell Therapeutics)")
The difference between the consensus estimate and the actual stock price CHRO (Chromocell Therapeutics)
Chromocell (CHRO) is a biotech company developing drugs to treat chronic pain using its unique R&D platform. This chart measures the gap between the current price and the consensus target price. It shows the potential (and risks) analysts see in their R&D portfolio for this complex market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CHRO-Chromocell-Therapeutics&v=1772628035928 "A chart showing the difference between the consensus forecast and the actual stock price. CHRO (Chromocell Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Chromocell (CHRO) is a biotech company developing non-opioid drugs for the treatment of chronic pain. This is high-risk R&D. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe in a breakthrough in R&D in pain treatment or consider this market an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Chromocell (CHRO) is a clinical-stage biopharmaceutical company focused on treating rare neurological diseases and pain. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Chromocell Therapeutics
Chromocell is a biotech R&D company focused on pain. Their R&D pipeline (NaV1.7 inhibitors) targets non-opioid mechanisms for treating chronic pain. This chart is purely an R&D barometer. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline, their clinical trial data, and their chances of success.
AKIMA Market Segment Index - Neuro
Chromocell Therapeutics is a biopharmaceutical company focused on pain and neurological disorders. They use their unique screening platform to discover new non-opioid analgesics. This chart compares their composite index to the sector, showing how their neuroscience approach compares to others.
The AKIM Index for the overall market
Chromocell Therapeutics is a biotech company developing non-opioid analgesics (NaV1.7 blockers) for pain treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this early scientific history compares to overall economic trends.
